Page results
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
A patient with motor neurone disease was able to control a computer just by using his thoughts following the UK’s first Neuralink implant surgery at UCLH’s National Hospital for Neurology and Neurosurgery (NHNN) in October 2025.
-
A new toolkit to support babies, children and young people in healthcare access high quality health play services was launched at UCLH last week with UCLH chief nurse Vanessa Sweeney welcoming visitors from NHS England and the play charity Starlight.
-
Update about our hospital on Gray's Inn Road
-
Lizzi Jordan, who received life-saving treatment at UCLH before going on to win a gold medal for cycling in the 2024 Paralympic Games, paid tribute to UCLH staff as she was made a Member of the British Empire (MBE).
-
At University College London Hospitals NHS Foundation Trust (UCLH) we value our reputation for top quality care and financial probity and conduct our business in an ethical manner.
-
Information for patients from overseas visiting UCLH hospitals.
-
Health secretary Matt Hancock visited University College Hospital yesterday to see for himself our post-Covid-19 service set up to help survivors of the virus with their long-term recovery.
File results
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details
-
FOI/2024/0363 - Freedom of Information responses available for Mesh requests
-
FOI/2024/0361 - Recording RTT waiting times: Planned patients guidance
-
FOI/2024/0403 - Risk Policy and corporate risk register
-
FOI/2024/0357 - Multiple myeloma treatments
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer